Pretreatment of GBM cells with 10 nM of CARF, partially reverted, the TRPML2-mediated pRB reduction, by increasing the hypophosphorylated-pRb form and total pRB levels as well as the hypo/hyperphosphorylated-pRb ratio. Here, RB1 is linked to glioblastoma.